Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled dose-finding study of BI 1358894 in borderline personality disorder
MOH_2021-05-04_009935Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bi 1358894 in borderline personality disorder (BPD) (5 arms), sponsored by Boehringer Ingelheim. Started Apr 2021; status: completed.
02
Drugs
bi 1358894
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on MOH_2021-05-04_009935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-05-04_009935.